Monopar Therapeutics (MNPR) Total Non-Current Liabilities (2020 - 2026)

Monopar Therapeutics (MNPR) posted Total Non-Current Liabilities of $2.9 million for Q4 2025, up 9.5% sequentially from $2.6 million in Q3 2025, and down 44.99% YoY from $5.3 million in Q4 2024.

Monopar Therapeutics (MNPR) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Monopar Therapeutics has reported Total Non-Current Liabilities for 3 years, with the latest figure at $2.9 million in Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 44.99% year-over-year to $2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (down 44.99% YoY) and the FY2025 annual result came in at $2.9 million, down 44.99% from the prior year.
  • Total Non-Current Liabilities grew to $2.9 million in Q4 2025 per MNPR's latest filing, from $2.6 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $5.3 million in Q4 2024 and troughed at $1.5 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Monopar Therapeutics 965.64 Mn 912.88 Mn - 4.12 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 4.12 Mn
Dec 31, 2025 2.89 Mn
Sep 30, 2025 2.64 Mn
Jun 30, 2025 1.66 Mn
Mar 31, 2025 1.49 Mn
Dec 31, 2024 5.25 Mn
Sep 30, 2020 54,628.00
Jun 30, 2020 75,021.00